Strengthening Marketing Collaboration with Local Partners
Boryung announced on the 27th that it introduced the efficacy of the new hypertension drug 'Kanarb Family' at the 'International Conference on Cardiovascular Interventional Procedures (CADECI)' held in Mexico on the 23rd (local time). Through this, Boryung plans to expand prescriptions of the new hypertension drug 'Kanarb Family' in Mexico and other Latin American countries.
At the event, cardiovascular specialists from Korea and Mexico shared clinical effects and prescription cases of the Kanarb product line. In particular, Boryung explained that clinical results on Kanarb’s proteinuria effect added as an indication beyond hypertension, Kanarb’s effect on reducing stroke recurrence and cardiovascular disease risk, and Kanarb’s efficacy in elderly hypertensive patients were introduced.
Boryung plans to increase the local market share of the Kanarb Family in Mexico by expanding the product lineup and strengthening marketing. Through cooperation with its local partner Stendhal, Boryung signed a memorandum of understanding (MOU) for the local launch of 'Ducarb Plus' within this year in Mexico. Ducarb Plus, launched domestically in June last year, is one of Boryung’s combination drugs based on the new hypertension drug 'Kanarb'. It is the first triple combination hypertension drug containing the main ingredient of Kanarb, ‘Pimasartan’, combined with the calcium channel blocker (CCB) ‘Amlodipine’ and the diuretic ‘Hydrochlorothiazide’.
The Latin American market, including Mexico, is experiencing rapid growth in pharmaceutical demand and has a high dependence on imported medicines, making it a representative emerging pharmaceutical market. Boryung explained that the demand for related medicines is increasing as the incidence of chronic diseases rises, with about 40% of the entire Mexican population suffering from hypertension.
Currently, in Mexico, Kanarb (local name Araco) was launched in 2014, Kanarb Plus (local name Diaraco) in 2016, Ducarb (local name Araco Duo) in 2019, and Tubero (local name Araco Pre) in 2020. The cumulative local sales of the Kanarb Family in Mexico have reached approximately 150 million USD (about 200 billion KRW) to date.
According to the pharmaceutical market research firm Ubist, the Kanarb Family recorded sales of 141.8 billion KRW domestically last year, ranking first in prescription amount among domestic new drugs and also ranking first among domestic family drug groups. Additionally, it holds the largest amount of clinical data among domestic new drugs, securing 124 domestic and international papers and over 50,000 cases.
Boryung and Stendhal plan to actively increase the market share of the Kanarb Family in Mexico based on its excellent therapeutic outcomes and diverse clinical evidence. Furthermore, both companies are preparing to enter the public insurance market to rapidly expand the Kanarb Family’s market, which is currently prescribed only in the local private insurance market.
Jang Doo-hyun, CEO of Boryung, stated, "Kanarb Family, the top prescribed domestic new drug, is steadily growing in the Mexican market and is regarded as a model case for pharmaceutical entry into Latin America. We will continue to strengthen cooperation with Stendhal and increase the market share in Mexico through expanding the Kanarb lineup."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
